Kerry Taylor
About
Kerry Taylor is a scholar working on Hematology, Genetics and Rheumatology.
According to data from OpenAlex, Kerry Taylor has authored 23 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 17 papers in Genetics and 4 papers in Rheumatology. Recurrent topics in Kerry Taylor's work include Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Acute Myeloid Leukemia Research (7 papers). Kerry Taylor is often cited by papers focused on Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Acute Myeloid Leukemia Research (7 papers). Kerry Taylor collaborates with scholars based in Australia, United States and New Zealand. Kerry Taylor's co-authors include Matteo Giovanni Della Porta, Mathias Schmid, Christian Rosé, Gabor Domokos, Agnès Guerci‐Bresler, Norbert Gattermann, Carlo Finelli, Pierre Fenaux, Bernard Roubert and Arnold Ganser and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.
In The Last Decade
Kerry Taylor
23 papers receiving 365 citations
Peers
Kerry Taylor
Valentina Giai Italy
Giancarla Gerli Italy
Joyce Chan China
Virginia Reyes‐Núñez Mexico
Cathy G. Rosenfield United States
Douglas Joshua Australia
Peter Schuld Germany
Alessandra Salvioni Italy
Mahmoud Elsawy United States
Stéphane Darre France
Citations per year, relative to Kerry Taylor Kerry Taylor (= 1×)
peers
Valentina Giai
Countries citing papers authored by Kerry Taylor
Since
Specialization
Citations
This map shows the geographic impact of Kerry Taylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerry Taylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerry Taylor more than expected).
Fields of papers citing papers by Kerry Taylor
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kerry Taylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerry Taylor. The network helps show where Kerry Taylor may publish in the future.
Co-authorship network of co-authors of Kerry Taylor
This figure shows the co-authorship network connecting the top 25 collaborators of Kerry Taylor. A scholar is included among the top collaborators of Kerry Taylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerry Taylor. Kerry Taylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lasica, Masa, Abbey Willcox, Kate Burbury, et al.. (2019). The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leukemia & lymphoma. 60(7). 1796–1802.
2.
Kenealy, Melita, Mark Hertzberg, Kerry Taylor, et al.. (2018). Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. Haematologica. 104(4). 700–709.
3.
Barras, Michael, et al.. (2013). Reducing the risk of harm from intravenous potassium: A multi-factorial approach in the haematology setting. Journal of Oncology Pharmacy Practice. 20(5). 323–331.
4.
Iland, Harry, K. F. Bradstock, John F. Seymour, et al.. (2011). Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 97(2). 227–234.
5.
Gattermann, Norbert, Carlo Finelli, Matteo Giovanni Della Porta, et al.. (2010). Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leukemia Research. 34(9). 1143–1150.
6.
Gattermann, Norbert, Mathias Schmid, Matteo Giovanni Della Porta, et al.. (2008). Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial. Blood. 112(11). 633–633.
7.
Seymour, John F., Andrew Grigg, John Reynolds, et al.. (2006). Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML.. Blood. 108(11). 2147–2147.
8.
Branford, Susan, Timothy P. Hughes, Anthony P. Schwarer, et al.. (2006). Significant Reduction of BCR-ABL Transcripts after Switching to Imatinib Therapy in Patients with CML and Complete or Near-Complete Cytogenetic Responses to Interferon-Alpha (IFN).. Blood. 108(11). 2142–2142.
9.
Kotasek, Dusan, J.-L. Canon, Jesús F. San Miguel, et al.. (2004). Correction/Maintenance Dosing (Front Loading) of Darbepoetin alfa: Final Results from a Randomized Phase 3 Active Controlled Trial.. Blood. 104(11). 1636–1636.
10.
Branford, Susan, Zbigniew Rudzki, Andrew Grigg, et al.. (2004). The Frequency of Detection of BCR-ABL Mutations in Imatinib Treated Patients with Chronic Phase CML Who Attain a Complete Cytogenetic Response (CCR) Does Not Diminish with Increasing Duration of CCR but the Associated Loss of Response Is Usually Gradual.. Blood. 104(11). 271–271.
11.
Branford, Susan, Zbigniew Rudzki, Andrew Grigg, et al.. (2004). BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who Achieve a Major Molecular Response.. Blood. 104(11). 274–274.
12.
Lickliter, Jason D., Chris Arthur, James D’Rozario, et al.. (2004). Phase II Pilot Study of Imatinib Mesylate Combined with Induction Chemotherapy in Blast-Phase CML and Ph+ ALL.. Blood. 104(11). 4682–4682.
13.
Seymour, John F., Andrew Grigg, John Reynolds, et al.. (2004). Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML.. Blood. 104(11). 1020–1020.
14.
Hughes, Timothy P., Susan Branford, John Reynolds, et al.. (2004). Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS.. Blood. 104(11). 1001–1001.
15.
Bentley, Michael A., Kerry Taylor, Andrew Grigg, et al.. (1999). Long-Term Interferon-Alpha 2A Does not Induce Sustained Hematologic Remission in Younger Patients with Essential Thrombocythemia. Leukemia & lymphoma. 36(1-2). 123–128.
16.
Mills, Anthony K., Kerry Taylor, Susan Wright, et al.. (1999). Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Australian and New Zealand Journal of Medicine. 29(1). 29–35.
17.
Hughes, Timothy P., Andrew Grigg, Jeff Szer, et al.. (1997). Mobilization of predominantly Philadelphia chromosome‐negative blood progenitors using cyclophosphamide and rHUG‐CSF in early chronic‐phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. British Journal of Haematology. 96(3). 635–640.
18.
Taylor, Kerry, R. Rodwell, Debra L. Taylor, et al.. (1995). Normal (RT-PCR negative) stem cells can be collected following lenograstim therapy in chronic myeloid leukemia (CML) in major/complete cytogenetic response (MCR/CCR) on alpha-interferon (alpha-IFN).. Blood. 86(10). 3955–3955.
19.
Singh, Manpreet, et al.. (1994). Myelodysplasia with myelofibrosis — A distinct subgroup within the myelodysplastic syndromes. Pathology. 26(1). 69–71.
20.
White, Karen L., James S. Wiley, Jan McKendrick, et al.. (1992). All-trans retinoic acid in the treatment of acute promyelocytic leukaemia.. PubMed. 22(5). 449–54.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Valentina Giai Breakdown of academic impact, for papers by Giancarla Gerli Breakdown of academic impact, for papers by Joyce Chan Breakdown of academic impact, for papers by Virginia Reyes‐Núñez Breakdown of academic impact, for papers by Cathy G. Rosenfield Breakdown of academic impact, for papers by Douglas Joshua Breakdown of academic impact, for papers by Peter Schuld Breakdown of academic impact, for papers by Alessandra Salvioni Breakdown of academic impact, for papers by Mahmoud Elsawy Breakdown of academic impact, for papers by Stéphane Darre